Home  |  About Us  |  News  |  FAQ  |  Contact Us  |  Careers @ GenesisCare

LoDoCo2 Trial

LoDoCo2 Trial

If you have coronary disease you may be eligible to take part in our innovative clinical research.

The Cardiologists in our practice are now inviting 3000 people with stable coronary disease to take part in the next phase of our ground-breaking clinical research into the possible prevention of Heart Attacks and Strokes. The LoDoCo2 trial follows our initial pilot study which demonstrated that Low Dose Colchicine reduced the risk of Heart Attacks and Strokes. Compared to the pilot study, LoDoCo2 is larger and has a more robust design. If positive it will have a major worldwide impact on the treatment of coronary disease.

If you agree to take part in this study you will be asked to try low dose colchicine for 30 days and if you have no untoward effects you will be enrolled into the actual study. If enrolled you will be randomly assigned to take either colchicine or an inactive tablet daily for the 3-4 year duration of the study. The tablets will be provided at no cost and will only need to be collected twice a year from any of our practice locations which may coincide with your usual clinic review.

Your usual treatment will not be affected and no blood tests or extra clinic visits are required. You can opt out of the trial at any point. To enrol: You must first speak with your Cardiologist and sign the trial consent form. Your involvement in this study will help us determine whether it is truly possible to further reduce the risk of Heart Attacks and Strokes in people with coronary disease.

Interested? – Read this brochure

Colchicine for Secondary Prevention of Cardiovascular Disease - Stefan M. Nidorf & John W. Eikelboom & Peter L. Thompson - Download PDF

Targeting Cholesterol Crystal-Induced Inflammation for the Secondary - Prevention of Cardiovascular Disease - Download PDF

Cooling Off Hot Hearts: A Specific Therapy for Vulnerable Plaque? - Download PDF

Anti-inflammatory therapies for cardiovascular disease - Paul M. Ridker 1, 2* and Thomas F. Lu¨ scher3 - Download PDF